1824-72-2

Usage

Uses

Used in Pharmaceutical Industry:
4,5-Dihydro-1H-benzo[e][1,4]diazepin-2(3H)-one is used as a therapeutic agent for the treatment of anxiety disorders, providing relief by reducing anxiety levels and promoting a sense of calm.
Used in Sleep Aid Applications:
In the pharmaceutical industry, 4,5-Dihydro-1H-benzo[e][1,4]diazepin-2(3H)-one is utilized as a sleep aid, helping to alleviate insomnia by inducing sleep and improving sleep quality.
Used in Seizure Management:
4,5-Dihydro-1H-benzo[e][1,4]diazepin-2(3H)-one is employed as an anticonvulsant in the treatment of seizures, working to prevent or reduce the frequency and severity of seizure episodes.
Used in Muscle Relaxation:
4,5-DIHYDRO-1H-BENZO[E][1,4]DIAZEPIN-2(3H)-ONE is used as a muscle relaxant to alleviate muscle spasms and tension, providing relief in conditions characterized by muscle stiffness and discomfort.

InChI:InChI=1/C9H10N2O/c12-9-6-10-5-7-3-1-2-4-8(7)11-9/h1-4,10H,5-6H2,(H,11,12)

Upstream product

• 88-72-2 1-methyl-2-nitrobenzene 
• 3958-60-9 2-nitrophenylmethyl bromide 
• 179686-64-7 methyl N-(2-nitrobenzyl)glycinate 
• 1174568-18-3 methyl N-(tert-butoxycarbonyl)-N-(2-nitrobenzyl)glycinate 
• 179686-65-8 methyl N-(2-aminobenzyl)-N-(tert-butoxycarbonyl)glycinate 
• 179686-66-9 tert-butyl 2-oxo-1,2,3,5-tetrahydro-4H-1,4-benzodiazepine-4-carboxylate 

Downstream Products

• 5946-39-4 2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine 

Relevant academic research and scientific papers

HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS

The present invention is directed to heterocyclic compounds which are antagonists of CGRP receptors and may be useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Design, synthesis, and pharmacological evaluation of fused β-homophenylalanine derivatives as potent DPP-4 inhibitors

Dipeptidyl peptidase-4 (DPP-4) inhibitors are accepted as a favorable class of agents for the treatment of type 2 diabetes. Herein, a series of fused β-homophenylalanine derivatives as novel DPP-4 inhibitors were designed, synthesized, and evaluated for their inhibitory activities against DPP-4. Most of them displayed excellent DPP-4 inhibitory activities and good selectivity. Among them, 9aa, 18a, and 18m also showed good efficacy in an oral glucose tolerance test (OGTT) in ICR mice. Moreover, when dosed 8 h prior to glucose challenge, 18m showed significantly greater potency than sitagliptin. It thus provides potential candidates for the further development into potent drugs targeting DPP-4.